Gastric Cancer
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3) Protocol No.: CAAA601A62301
- Details
ClinicalTrials.gov ID:
NCT06784752
Diagnosis Type:
NA
USOR Number:
- Address
,
P: